Evaluation of factors affecting epidermal growth factor receptor tyrosine kinase inhibitor-induced hepatotoxicity in Japanese patients with non-small cell lung cancer: a two-center retrospective study

• Main Authors: Hirofumi Nagai (Author), Tsutomu Shimada (Author), Yoshimitsu Takahashi (Author), Mikako Nishikawa (Author), Hiroyuki Tozuka (Author), Yasuto Yamamoto (Author), Osamu Niwa (Author), Yutaka Takahara (Author), Arimi Fujita (Author), Katsuhiko Nagase (Author), Kazuo Kasahara (Author), Seiji Yano (Author), Yoshimichi Sai (Author)
• Format: Book
• Published: BMC, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Gefitinib and erlotinib, are epidermal growth factor receptor tyrosine kinase inhibitors, and are currently recommended for non-small cell lung cancer stage IV in the elderly and in patients with decreased performance status in the Japanese Lung Cancer Society Guideline, but they...